Who Needs Closer Monitoring for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Risk Assessment

If you or a loved one is taking Tysabri, you may be wondering about the risk of progressive multifocal leukoencephalopathy (PML) and who needs closer monitoring. The medical community has long recognized that understanding treatment exposure is critical to assessing patient risk. This page provides context on how dose and duration of Tysabri therapy relate to PML reports, helping you have informed discussions with your healthcare provider.

Understanding Tysabri and Its Mechanism of Action

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn disease in adults. The prescribing information for Tysabri carries a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs when the JC virus infects and destroys oligodendrocytes, the cells that produce myelin in the central nervous system. Clinical presentation of PML typically includes subacute onset of neurologic deficits such as cognitive decline, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The mechanistic pathway linking Tysabri to PML involves its pharmacologic action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JCV in the brain. Under normal conditions, JCV is controlled by a competent immune system. By limiting T-cell trafficking into the brain, Tysabri creates an immunocompromised environment that allows JCV to reactivate and cause PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Factors and Clinical Presentation of PML

Three established risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The risk increases with cumulative exposure, and the boxed warning instructs healthcare professionals to consider these factors in the context of expected benefit when initiating and continuing treatment. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The boxed warning explicitly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability. It also mandates that healthcare professionals monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether prescribers adequately communicated the risk to patients, whether monitoring protocols were followed, and whether the drug was continued in the presence of early symptoms that could have indicated PML onset.

Statute of Limitations for Tysabri Claims in Florida

For patients who develop PML after Tysabri exposure, the timeline between exposure and documented harm is variable. PML typically occurs after months to years of treatment, with risk increasing beyond two years of therapy. The latency period complicates the attribution of harm to the drug, as symptoms may emerge gradually and be mistaken for multiple sclerosis relapse or other conditions. FDA adverse-event reports for Tysabri frequently include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms overlap with PML presentation, underscoring the need for prompt diagnostic evaluation when neurologic changes occur. Attorney-related considerations for affected patients in Florida involve the statute of limitations for filing a product liability or medical malpractice claim. In Florida, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For claims involving Tysabri-associated PML, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that the injury was caused by the drug. Given the latency of PML and the potential for delayed diagnosis, patients should consult with an attorney experienced in pharmaceutical litigation to assess their specific timeline. Factors such as the date of Tysabri initiation, the date of PML diagnosis, and the date when the link to Tysabri was recognized are critical for determining whether a claim is timely.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For Tysabri-associated PML, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that the injury was caused by the drug. Given the latency of PML, patients should consult an attorney promptly to evaluate their specific timeline.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative exposure.

How does Tysabri cause PML?

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus in the brain, allowing the virus to reactivate and cause PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.